New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
08:01 EDTSHPG, IPXLImpax, Shire settle litigation on supply of authorized generic Adderall XR
Impax Laboratories (IPXL) announced that it has settled all pending litigation with Shire LLC (SHPG) and Shire Laboratories, Inc.relating to supply of its authorized generic Adderall XR under the partiesí License and Distribution Agreement that was signed in January 2006. As part of the settlement, the parties will submit a stipulation of dismissal for entry by the Court. Shire has agreed to make a one-time cash payment to Impax of $48M upon the courtís order of dismissal. The parties have entered into an amended License and Distribution Agreement which will govern the future supply of authorized generic Adderall XR from Shire to Impax. Following the end of the supply term on September 30, 2014, Impax will continue to have the right to sell its products on hand or owed to it under the agreement until depleted and will continue to pay a profit share to Shire on sales of such products. Impax will continue to pursue approval of its pending Abbreviated New Drug Application for generic Adderall XR which was filed with the U.S. Food and Drug Administration in September 2003.
News For IPXL;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:04 EDTSHPGShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
January 26, 2015
08:21 EDTSHPGShire the 'real winner' after NPS gets approval for Natpara, says Janney Capital
Janney Capital said NPS Pharmaceuticals' (NPSP) getting FDA approval for its second marketed product, Natpara, is a positive for NPS, but that the "real winner" is Shire (SHPG), noting that the company had no stipulations dependent on Natpara approval in its deal to buy NPS. The firm expects the acquisition to move forward as planned and maintains its Neutral rating on NPS shares.
08:09 EDTIPXLImpax receives FDA approval for generic version of Lamictal tablets
Subscribe for More Information
07:27 EDTSHPGShire price target raised to $263 from $247 at Jefferies
Subscribe for More Information
05:26 EDTSHPGShire SHP609 receives FDA fast track designation
Subscribe for More Information
January 25, 2015
12:30 EDTSHPGShire comments on press release from NPS Pharma on Natpara approval
Subscribe for More Information
January 22, 2015
05:27 EDTSHPGShire reports positive response from European DCP for Elvanse Adult
Subscribe for More Information
January 20, 2015
14:06 EDTSHPGCitizens, Keysight identified as long positions by Einhorn
Subscribe for More Information
08:10 EDTSHPGShire price target raised to $247 from $228 at Jefferies
Subscribe for More Information
January 16, 2015
16:36 EDTSHPGMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use